Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 3, 2014, Pages 370-374

  Devillier, Raynier ^a,b,c   Fürst, Sabine ^a   El Cheikh, Jean ^a   Castagna, Luca ^a,d   Harbi, Samia ^a,b   Granata, Angela ^a   Crocchiolo, Roberto ^a,d   Oudin, Claire ^a,b   Mohty, Bilal ^a   Bouabdallah, Reda ^a   Chabannon, Christian ^a,b,c   Stoppa, Anne Marie ^a   Charbonnier, Aude ^a   Broussais Guillaumot, Florence ^a   Calmels, Boris ^a,c   Lemarie, Claude ^a   Rey, JèrÔme ^a   Vey, Norbert ^a,b,c   Blaise, Didier ^a,b,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Allogeneic stem cell transplantation; Antithymocyte globulin; Reduced intensity conditioning

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; FLUDARABINE PHOSPHATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RELAPSE; RISK ASSESSMENT; YOUNG ADULT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTITHYMOCYTE GLOBULIN; REDUCED-INTENSITY CONDITIONING;

ADULT; AGED; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC AGENTS; BUSULFAN; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 84896885319     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.030     Document Type: Article

References (31)

1. Lowsky R., Takahashi T., Liu Y.P., et al. Protective conditioning for acute graft-versus-host disease. NEngl J Med 2005, 353:1321-1331.
2. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
3. Chakraverty R., Peggs K., Chopra R., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002, 99:1071-1078.
4. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
5. Blaise D., Farnault L., Faucher C., et al. Reduced-intensity conditioning with Fludarabin, oral busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. Exp Hematol 2010, 38:1241-1250.
6. Blaise D., Tabrizi R., Boher J.M., et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer 2013, 119:602-611.
7. Crocchiolo R., Esterni B., Castagna L., et al. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. Cancer 2013, 119:986-992.
8. Devillier R., Crocchiolo R., Castagna L., et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 2012, 47:639-645.
9. Devillier R., Furst S., Crocchiolo R., et al. Aconditioning platform based on fludarabine, busulfan and two days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. Am J Hematol 2013, 10.1002/ajh.23592.
10. Armand P., Gibson C.J., Cutler C., et al. Adisease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012, 120:905-913.
11. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
12. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974, 18:295-304.
13. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
14. Fine J. Aproportional hazards model for the subdistribution of a competing risk. JAm Stat Assoc 1999, 94:496-509.
15. Gooley T.A., Leisenring W., Crowley J., et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
16. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
17. Cox D.R. Regression models and life tables. JR Stat Soc B 1972, 34:187-220.
18. Storb R., Gyurkocza B., Storer B.E., et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. JClin Oncol 2013, 31:1530-1538.
19. El Kourashy S., Williamson T., Chaudhry M.A., et al. Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG. Bone Marrow Transplant 2011, 46:1077-1083.
20. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
21. Russell J.A., Turner A.R., Larratt L., et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 2007, 13:299-306.
22. Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002, 30:681-686.
23. Venton G., Crocchiolo R., Furst S., et al. Risk factors of ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. Clin Microbiol Infect 2013, 10.1111/1469-0691.12222.
24. Gyurkocza B., Storb R., Storer B.E., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. JClin Oncol 2010, 28:2859-2867.
25. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000, 6:548-554.
26. Andersson B.S., Kashyap A., Gian V., et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002, 8:145-154.
27. Thall P.F., Champlin R.E., Andersson B.S. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant 2004, 33:1191-1199.
28. Alatrash G., de Lima M., Hamerschlak N., et al. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 2011, 17:1490-1496.
29. Andersson B.S., de Lima M., Thall P.F., et al. Once-daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 14:672-684.
30. Liu H., Zhai X., Song Z., et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. JHematol Oncol 2013, 6:15.
31. Blaise D., Castagna L. Do different conditioning regimens really make a difference?. Hematology Am Soc Hematol Educ Program 2012, 2012:237-245.